VCEL · CIK 0000887359
What Vericel Corporation told the SEC could break it.
Vericel's risks are about single points of failure in fragile supply chains. All of its commercial manufacturing for its two autologous cell therapies, MACI and Epicel, runs through one facility in Cambridge, Massachusetts — and because these are personalized, living-cell products on tight patient-specific timelines, a disruption there would halt supply with no quick alternative (it is bringing a second Burlington site online to mitigate). Its NexoBrid burn biologic depends on an even longer, single-threaded chain — bromelain sourced from Taiwan, the product manufactured by MediWound primarily in Israel — so disruption at any link could limit its availability, while its revenue is also moderately concentrated, with one customer about 13% of 2025 revenue.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Commodity & input dependence
- NexoBrid active ingredient (bromelain) sourced from Taiwan; product manufactured by MediWound in Israel — a Taiwan→Israel→US supply chain for a sole-source biologicmedium
Vericel's NexoBrid (orphan burn-debridement biologic) depends on a geographically extended, single-threaded supply chain: certain raw materials for NexoBrid's manufacture — including the active ingredient bromelain — are sourced from Taiwan (the Bromelain SP supplied via CBC to MediWound), and NexoBrid itself is manufactured by MediWound primarily in Israel. Disruption at any link — a Taiwan bromelain shortage, a change in CBC supply/demand, or conflict-driven damage to MediWound's Israeli facilities — could limit NexoBrid availability to Vericel. A specific, cross-border raw-material/active-ingredient dependence bridging Taiwan and Israel.
“Certain raw materials utilized in NexoBrid's manufacture, including the supply of the active ingredient bromelain, are sourced from Taiwan.”
Customer concentration
- One customer accounted for ~13% of revenue and ~11% of accounts receivable in 2025 (unnamed)medium
Vericel discloses a single-customer concentration: one (unnamed) customer represented approximately 13% of total revenue and 11% of accounts receivable for 2025 (11%/10% in 2024). For a company whose products (MACI implants, Epicel, NexoBrid) are ultimately administered by hospitals and reimbursed by payers, this likely reflects a large hospital system or specialty distributor. The customer is not named in the filing, so this is captured as a concentration risk rather than an edge; loss of or a change at that customer would have a bounded but meaningful revenue impact. A moderate customer concentration.
“The Company's total revenue and accounts receivable concentrations from a single customer consisted of the following:”
SEC filing →As of 2026
Geographic concentration
- All commercial manufacturing of MACI and Epicel performed at a single facility in Cambridge, Massachusetts — single point of failure for patient-specific autologous cell therapymedium
Vericel performs all commercial manufacturing of its two cell-therapy products — MACI (autologous cultured chondrocytes) and Epicel — at a single U.S. facility in Cambridge, Massachusetts. Because these are personalized, living-cell autologous products with tight, patient-specific timelines, a disruption (fire, contamination, equipment, regulatory action) at the sole site would directly halt the supply of life-altering/-saving therapies with no quick alternative. The company is bringing on a second facility in Burlington, MA (under utilization) to mitigate, but as of the filing the single-site concentration remains. A genuine single-facility manufacturing concentration with a severe failure mode.
“We presently conduct all of our commercial manufacturing operations for MACI and Epicel in the U.S., at one facility located in Cambridge, Massachusetts.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
“After the Initial Term and optional two-year extension, Vericel, at its sole discretion, may choose to extend the Supply Agreement's term for additional one-year period for a potential total term of fifteen years.”
Cited →“we entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America.”
Cited →Matricel GmbH
“Matricel is the sole supplier of the membrane for MACI.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch